Clinical Trial Update: Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update on SRX246 assessing tolerability, safety, and activity in irritable mood associated with Huntington's disease; study completed with posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• SRX246

Snippet

Sponsor: Azevan Pharmaceuticals | Conditions: Irritable Mood, Huntington's Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-07-20